ReviewFrontiers in endocrinology2021
Phytochemicals as Potential Epidrugs in Type 2 Diabetes Mellitus.
Review in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Dietary Polyphenols and In Vitro Intestinal Fructose Uptake and Transport: A Systematic Literature Review.International journal of molecular sciences · 2022Pooled it
- Harnessing Medicinal Plants Through Advanced Drug Delivery: A New Era in Type 2 Diabetes Management.Pharmaceutics · 2026Review
- Harnessing Phytochemicals and Nanotechnology Synergy for Molecular, Epigenetic, and Microbiota-Driven Regulation in Type 2 Diabetes Mellitus.Pharmaceutics · 2026Review
- The beneficial Effects ofCurrent diabetes reviews · 2026Article
- Mechanistic Insights into Antioxidant Interventions Targeting Obesity-Induced Oxidative Stress in the Pathogenesis and Complications of Type 2 Diabetes Mellitus.Current issues in molecular biology · 2025Review
- Construction and validation of a hypoglycemia risk prediction model for hospitalized type 2 diabetes patients based on machine learning.BMC endocrine disorders · 2025Article
- Exploring Holy Basil's Bioactive Compounds for T2DM Treatment: Docking and Molecular Dynamics Simulations with Human Omentin-1.Cell biochemistry and biophysics · 2025Article
- The application of procyanidins in diabetes and its complications: a review of preclinical studies.Frontiers in pharmacology · 2025Review
- Recent Progress on Natural α-Glucosidase Inhibitors Derived from the Plants and Microorganisms.Current medicinal chemistry · 2025Review
- "Hyperglycemic Memory": Observational Evidence to Experimental Inference.Current diabetes reviews · 2025Review
- Mechanism of Jianpixiaoke Recipe in Treating Type 2 Diabetes Based on Network Pharmacology and Molecular Docking.International journal of endocrinology · 2025Article
- Epigenetic repurposing of carbohydrate metabolic inhibitors for insulin resistance: targeting DNMT1 and HDAC3 for β-cell restoration.Frontiers in epigenetics and epigenomics · 2025Review
- Effects of Phytochemicals on Type 2 Diabetes via MicroRNAs.Current nutrition reports · 2024Review
- Article
- Identification of antidiabetic inhibitors fromSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Targeting the Epigenetic Marks in Type 2 Diabetes Mellitus: Will Epigenetic Therapy Be a Valuable Adjunct to Pharmacotherapy?Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Herbal medications and natural products for patients with covid-19 and diabetes mellitus: Potentials and challenges.Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2022Review
- Antidiabetic Activity of Mung Bean orEvidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes Mellitus (T2DM) prevalence has significantly increased worldwide in recent years due to population age, obesity, and modern sedentary lifestyles. The projections estimate that 439 million people will be diabetic in 2030. T2DM is characterized by an impaired β-pancreatic cell function and insulin secretion, hyperglycemia and insulin resistance, and recently the epigenetic regulation of β-pancreatic cells differentiation has been underlined as being involved. It is currently known that several bioactive molecules, widely abundant in plants used as food or infusions, have a key role in histone modification and DNA methylation, and constituted potential epidrugs candidates against T2DM. In this sense, in this review the epigenetic mechanisms involved in T2DM and protein targets are reviewed, with special focus in studies addressing the potential use of phytochemicals as epidrugs that prevent and/or control T2DM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.